Rizatriptan benzoat

• Anti-migraine Agents
• Vasoconstrictor Agents
• Anti-inflammatory Agents
• Selective Serotonin Agonists
• ATC:N02CC04

• Maxalt
• Maxalt-MLT
• MK 462 Free Base
• Risatriptan
• Rizatriptan benzoat
• Rizatriptan benzoate

• No information avaliable

C₁₅H₁₉N₅

http://www.rxlist.com/cgi/generic2/rizatrip.htm

Rizatriptan_benzoat FDA

Rizatriptan_benzoat MSDS

No information avaliable

269.345 g/mol

178-180 ^oC

42 mg/mL (for free base)

Solid

2.129

Tablet; Wafer

For treatment of acute migraine attacks.

Rizatriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Rizatriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Rizatriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT_1D family) having only a weak affinity for 5-HT_1A, 5-HT_5A, and 5-HT₇ receptors and no significant affinity or pharmacological activity at 5-HT₂, 5-HT₃ or 5-HT₄ receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Rizatriptan also activates 5-HT₁ receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Rizatriptan in humans.

Rapid following oral administration. Bioavailability is 45%. Food has no effect on the bioavailability of rizatriptan. However, administering rizatriptan with food will delay by 1 hour the time to reach peak plasma concentration. The rate of absorption is not affected by the presence of a migraine attack.

Symptoms of overdose include dizziness, fainting, heart and blood vessel problems, high blood pressure, loss of bowel and bladder control, slow heartbeat, and vomiting.

Migraine or treatment with MAXALT may cause somnolence in some patients. Dizziness has also been reported in some patients receiving MAXALT. Patients should, therefore, evaluate their ability to perform complex tasks during migraine attacks and after administration of MAXALT. Physicians should instruct their patients to read the patient package insert before taking MAXALT.

Humans and other mammals